News & Videos - ABBVIE INC. - English

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical...

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 SHANGHAI and NORTH CHICAGO, Ill. , Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical...

AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma PR Newswire NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 NORTH CHICAGO, Ill. and SHANGHAI , Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials...

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program PR Newswire NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 Pivotal data evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet age-related macular degeneration (wet AMD) are expected in 2026 AbbVie and REGENXBIO will plan the Phase 3 clinical program of investigational ABBV-RGX-314 in diabetic retinopathy (DR) NORTH CHICAGO, Ill. and ROCKVILLE, Md. , Jan. 13, 2025...

AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire NORTH CHICAGO, Ill., Jan. 9, 2025 NORTH CHICAGO, Ill. , Jan. 9, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 . Management will participate in a fireside chat at 10:15 a.m. Central time . A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An...

CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics PR Newswire IRVINE, Calif., Jan. 7, 2025 Get Treated with CoolSculpting ® Elite and Enter for a Chance to Win $10,000* Starting Today, First-Time Users Can Claim $300 Off Their Treatment † IRVINE, Calif. , Jan. 7, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its third annual CoolMonth featuring CoolSculpting ® Elite. The celebration is an opportunity for consumers interested in...

AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call PR Newswire NORTH CHICAGO, Ill., Jan. 3, 2025 NORTH CHICAGO, Ill. , Jan. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2024 financial results on Friday, January 31, 2025 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time . It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com . An...

AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline PR Newswire NORTH CHICAGO, Ill. and MADISON, Wis., Dec. 13, 2024 Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remain Acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the...

AbbVie Completes Acquisition of Aliada Therapeutics PR Newswire NORTH CHICAGO, Ill., Dec. 11, 2024 Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilities NORTH CHICAGO, Ill. , Dec. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the...

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma PR Newswire NORTH CHICAGO, Ill., Dec. 9, 2024 Data presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from two ongoing clinical trials evaluating...

AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease PR Newswire NORTH CHICAGO, Ill., Dec. 9, 2024 Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 26 1 Trial also met its key secondary endpoint, demonstrating statistically significant...

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients PR Newswire NORTH CHICAGO, Ill., Dec. 8, 2024 -New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic leukemia (CLL) diagnosis and treatment journeys - CLL is one of the most common leukemias among adults affecting more than 200,000 people in the U.S. 1,2 NORTH CHICAGO, Ill. , Dec. 8, 2024 /PRNewswire/ -- AbbVie...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) PR Newswire NORTH CHICAGO, Ill., Dec. 7, 2024 Data presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill. , Dec. 7, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 1b /2 EPCORE ® NHL-2 trial evaluating...

AbbVie to Present at Citi's 2024 Global Healthcare Conference PR Newswire NORTH CHICAGO, Ill., Nov. 25, 2024 NORTH CHICAGO, Ill. , Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 . Scott T. Reents , executive vice president, chief financial officer, Jeffrey R. Stewart , executive vice president, chief commercial officer and Roopal Thakkar , M.D., executive vice president, Research & Development and chief...

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products PR Newswire IRVINE, Calif., Nov. 18, 2024 Seven new e-trainings, all 30 minutes or less, are available starting today through Allergan Medical Institute® (AMI) at AMIOnline.com IRVINE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, launched AMI Business Education, a new addition to the AMI Online learning platform available for free to...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of April 2, 2025. In conjunction with the acceptance of the NDA for review, Aldeyra announced the...

AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer PR Newswire NORTH CHICAGO, Ill., Nov. 18, 2024 ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian...

AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations PR Newswire NORTH CHICAGO, Ill., Nov. 14, 2024 AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in migraine treatment, is committed to addressing the impact of migraine in the workplace Nearly 40 million Americans are living with migraine, a debilitating neurological disease,...

AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia PR Newswire NORTH CHICAGO, Ill., Nov. 11, 2024 EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial NORTH CHICAGO, Ill. , Nov. 11, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for...

Allergan Aesthetics Celebrates Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day PR Newswire IRVINE, Calif., Nov. 7, 2024 Last Year, BOTOX ® Cosmetic Day Set the Record for the Most BOTOX ® Cosmetic Gift Cards Sold in a Single Day 1 This Year, the Excitement Continues with New Offers to Refer a Friend Plus the Best-Selling Buy-One-Get-One (BOGO) Free Gift Card Offer Join Allē Today to Take Advantage of Exclusive Offers IRVINE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Allergan Aesthetics, an...